JP7684216B2 - ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用 - Google Patents

ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用 Download PDF

Info

Publication number
JP7684216B2
JP7684216B2 JP2021532503A JP2021532503A JP7684216B2 JP 7684216 B2 JP7684216 B2 JP 7684216B2 JP 2021532503 A JP2021532503 A JP 2021532503A JP 2021532503 A JP2021532503 A JP 2021532503A JP 7684216 B2 JP7684216 B2 JP 7684216B2
Authority
JP
Japan
Prior art keywords
seq
antigen
galnac
galactosaminidase
deacetylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021532503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532838A5 (enExample
JP2021532838A (ja
Inventor
サイペル，マルセロ
ワン，アイシュー
ケシャブジェ，シャフィク
ジー． ウィザーズ，スティーブン
ラフェルド，ピーター
キザッケダズ，ジャヤチャンドラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of JP2021532838A publication Critical patent/JP2021532838A/ja
Publication of JP2021532838A5 publication Critical patent/JP2021532838A5/ja
Priority to JP2025081746A priority Critical patent/JP2025131609A/ja
Application granted granted Critical
Publication of JP7684216B2 publication Critical patent/JP7684216B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01025—N-Acetylglucosamine-6-phosphate deacetylase (3.5.1.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Materials For Medical Uses (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021532503A 2018-08-17 2019-08-16 ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用 Active JP7684216B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025081746A JP2025131609A (ja) 2018-08-17 2025-05-15 ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719272P 2018-08-17 2018-08-17
US62/719,272 2018-08-17
PCT/CA2019/051121 WO2020034043A1 (en) 2018-08-17 2019-08-16 Enzymatic compositions for carbohydrate antigen cleavage on donor organs, methods and uses associated therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025081746A Division JP2025131609A (ja) 2018-08-17 2025-05-15 ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用

Publications (3)

Publication Number Publication Date
JP2021532838A JP2021532838A (ja) 2021-12-02
JP2021532838A5 JP2021532838A5 (enExample) 2022-08-23
JP7684216B2 true JP7684216B2 (ja) 2025-05-27

Family

ID=69524510

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021532503A Active JP7684216B2 (ja) 2018-08-17 2019-08-16 ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用
JP2021507883A Active JP7570316B2 (ja) 2018-08-17 2019-08-16 糖鎖抗原除去のための酵素組成物、それに関連する方法、使用、装置およびシステム
JP2024111653A Pending JP2024163994A (ja) 2018-08-17 2024-07-11 糖鎖抗原除去のための酵素組成物、それに関連する方法、使用、装置およびシステム
JP2025081746A Pending JP2025131609A (ja) 2018-08-17 2025-05-15 ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021507883A Active JP7570316B2 (ja) 2018-08-17 2019-08-16 糖鎖抗原除去のための酵素組成物、それに関連する方法、使用、装置およびシステム
JP2024111653A Pending JP2024163994A (ja) 2018-08-17 2024-07-11 糖鎖抗原除去のための酵素組成物、それに関連する方法、使用、装置およびシステム
JP2025081746A Pending JP2025131609A (ja) 2018-08-17 2025-05-15 ドナー臓器における糖鎖抗原除去のための酵素組成物、それに関連する方法および使用

Country Status (8)

Country Link
US (4) US20210324361A1 (enExample)
EP (2) EP3837370A4 (enExample)
JP (4) JP7684216B2 (enExample)
CN (4) CN112839512B (enExample)
AU (1) AU2019322933B2 (enExample)
BR (1) BR112021002899A2 (enExample)
CA (2) CA3109723A1 (enExample)
WO (2) WO2020034043A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116024183B (zh) * 2023-02-15 2023-10-31 中国农业科学院兰州兽医研究所 一种用于荧光染色的重组蓝舌病毒及其构建方法
WO2025213250A1 (en) * 2024-04-11 2025-10-16 The University Of British Columbia Enzymatic compositions for b antigen cleavage, methods, uses, apparatuses and systems associated therewith
JP2026057100A (ja) 2024-09-20 2026-04-02 トヨタ自動車株式会社 電気ユニット

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014038473A1 (ja) 2012-09-08 2014-03-13 株式会社オーガンテクノロジーズ 移植のための臓器又は組織の長期維持方法
US20150087061A1 (en) 2005-10-31 2015-03-26 Velico Medical, Inc. Methods of Preparing Tissues for Xenotransplantation Using Alpha-galactosidases
JP2016531910A (ja) 2013-08-16 2016-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド 移植前の臓器への補体阻害剤の投与による移植拒絶の処置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609627A (en) * 1983-08-01 1986-09-02 New York Blood Center, Inc. Enzymatic conversion of certain sub-type A and AB erythrocytes
CA2272925A1 (en) * 1996-11-21 1998-05-28 Jack Goldstein Method for conversion of blood type
US7767415B2 (en) * 2001-09-25 2010-08-03 Velico Medical, Inc. Compositions and methods for modifying blood cell carbohydrates
WO2007100294A1 (en) * 2006-02-28 2007-09-07 Kurt Nilsson Material system for blood products
CA2697999C (en) * 2009-04-24 2013-04-30 Werner Hoelke A stabilized aqueous alpha-galactosidase composition and methods relating thereto
CN107298699B (zh) * 2017-07-21 2020-09-11 天津大学 通过添加大分子拥挤试剂高效体外生物生产蛋白质的配方及方法
EP3962295A1 (en) * 2019-05-01 2022-03-09 The Procter & Gamble Company Probiotic bacterial strains that produce short chain fatty acids and compositions comprising same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150087061A1 (en) 2005-10-31 2015-03-26 Velico Medical, Inc. Methods of Preparing Tissues for Xenotransplantation Using Alpha-galactosidases
WO2014038473A1 (ja) 2012-09-08 2014-03-13 株式会社オーガンテクノロジーズ 移植のための臓器又は組織の長期維持方法
JP2016531910A (ja) 2013-08-16 2016-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド 移植前の臓器への補体阻害剤の投与による移植拒絶の処置

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Database UniProtKB, Accession No. A0A096B2Z8, [online]，2017年11月22日，[2024年10月21日検索], インターネット<URL: https://rest.uniprot.org/unisave/A0A096B2Z8?format=txt&versions=12>
Database UniProtKB, Accession No. A0A174W0P5, [online]，2017年11月22日，[2024年10月21日検索], インターネット<URL: https://rest.uniprot.org/unisave/A0A174W0P5?format=txt&versions=9>
Nat. Microbiol.，2019年，Vol. 4，p. 1475-1485，Epub 2019 Jun 10
Proc. Japan Acad.，1968年，Vol. 44，p. 263-268

Also Published As

Publication number Publication date
EP3837370A4 (en) 2022-09-14
US20240294895A1 (en) 2024-09-05
CN112839512A (zh) 2021-05-25
CN119662602A (zh) 2025-03-21
WO2020034042A1 (en) 2020-02-20
CN112840027B (zh) 2025-01-10
CN112839512B (zh) 2023-06-13
AU2019322933A1 (en) 2021-03-18
CA3109723A1 (en) 2020-02-20
JP2025131609A (ja) 2025-09-09
US20210345601A1 (en) 2021-11-11
EP3852526A1 (en) 2021-07-28
AU2019322933B2 (en) 2025-08-14
EP3852526A4 (en) 2022-11-02
BR112021002899A2 (pt) 2021-05-11
CN117044707A (zh) 2023-11-14
JP2024163994A (ja) 2024-11-26
CA3116785A1 (en) 2020-02-20
CN112840027A (zh) 2021-05-25
US20210324361A1 (en) 2021-10-21
US20250011749A1 (en) 2025-01-09
EP3837370A1 (en) 2021-06-23
JP2021532838A (ja) 2021-12-02
JP2021533783A (ja) 2021-12-09
WO2020034043A1 (en) 2020-02-20
JP7570316B2 (ja) 2024-10-21

Similar Documents

Publication Publication Date Title
Rahfeld et al. An enzymatic pathway in the human gut microbiome that converts A to universal O type blood
US20240294895A1 (en) Enzymatic compositions for carbohydrate antigen cleavage on donor organs, methods and uses associated therewith
Rahfeld et al. Toward universal donor blood: Enzymatic conversion of A and B to O type
Shen et al. Structural analysis of the α-glucosidase HaG provides new insights into substrate specificity and catalytic mechanism
Echeverria et al. Chemoenzymatic synthesis of N-glycan positional isomers and evidence for branch selective binding by monoclonal antibodies and human C-type lectin receptors
Kwan et al. Toward efficient enzymes for the generation of universal blood through structure-guided directed evolution
Jing et al. Analysis of the two active sites of the hyaluronan synthase and the chondroitin synthase of Pasteurella multocida
Anso et al. Turning universal O into rare Bombay type blood
Jensen et al. Akkermansia muciniphila exoglycosidases target extended blood group antigens to generate ABO-universal blood
Loukachevitch et al. Structures of the Streptococcus sanguinis SrpA binding region with human sialoglycans suggest features of the physiological ligand
McCombs et al. Enhanced cross-linking of diazirine-modified sialylated glycoproteins enabled through profiling of sialidase specificities
Melcher et al. Revised domain structure of ulvan lyase and characterization of the first ulvan binding domain
US9182390B2 (en) Biomolecule-immobilized carrier and method for immobilizing biomolecule on carrier
Mariño et al. Identification, subcellular localization, biochemical properties, and high-resolution crystal structure of Trypanosoma brucei UDP-glucose pyrophosphorylase
Yeung et al. Kinetic and structural evaluation of selected active site mutants of the Aspergillus fumigatus KDNase (sialidase)
Humeidi et al. The ulcerative colitis-associated gene NXPE1 catalyzes glycan modifications on colonic mucin
Curci et al. Novel GH109 enzymes for bioconversion of group A red blood cells to the universal donor group O
Madoori et al. Purification, crystallization and preliminary X-ray diffraction analysis of the lytic transglycosylase MltF from Escherichia coli
Anso Miqueleiz Structural basis of bacterial glyeans biosynthesis and processing: ímpact in human health and disease
WO2025213250A1 (en) Enzymatic compositions for b antigen cleavage, methods, uses, apparatuses and systems associated therewith
Gregg Carbohydrate Processing by Bacterial Pathogens: Structural and Functional Analyses of Glycoside Hydrolases
Huff Interrogation of GH109 glycosidase specificity and activity through a synthetic gene library
Li et al. A unique Endo-β-galactosidase that cleaves both blood group A and B glycotopes
Hündling biochemical and structural studies of lectines from opportunistic filamentous fungi
Kornfeld et al. ER and Golgi membranes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250515

R150 Certificate of patent or registration of utility model

Ref document number: 7684216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150